TScan Therapeutics (NASDAQ:TCRX) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 3 | 0 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 1 | 1 | 0 | 0 | 0 |
3M Ago | 0 | 1 | 0 | 0 | 0 |
Analysts have recently evaluated TScan Therapeutics and provided 12-month price targets. The average target is $10.75, accompanied by a high estimate of $15.00 and a low estimate of $9.00. Surpassing the previous average price target of $7.00, the current average has increased by 53.57%.
Understanding Analyst Ratings: A Comprehensive Breakdown
The...
Login or create a forever free account to read this news
Sign up/Log in